摘要
目的探讨CT导引下经皮穿刺植入125I放射性粒子治疗肺癌的临床疗效、可行性及安全性。方法共67例肺癌91个病灶行CT引导下经皮植入125I放射性粒子。病灶位于肺部58个,肺外33个。采用0.5～0.8mCi(1mCi=37MBq)活度的125I粒子,处方剂量选择110～160Gy。术前通过放射性粒子治疗计划系统(TPS)制定治疗计划。结果91个病灶CR23个,PR60个,SD8个,无PD,有效率91.2%。主要并发症有气胸、少量咯血。结论CT引导下经皮植入125I放射性粒子治疗肺癌近期疗效确切、并发症轻,可作为肺癌多学科综合治疗中的一个方法。
Objective To evaluate the efficacy, feasibility and safety of CT guided percutaneous implantation of ^125Ⅰ seeds in treating lung cancer. Methods Clinical data of 67 patients with lung cancer undergone radioactive ^125Ⅰ seeds implantation were retrospectively analyzed, ^125Ⅰ seeds of 0. 5 -0. 8 mCi（ 1 mCi = 37 MBq） were used. Prescribed matched peripheral dose（MPD） was 110 - 160 Gy. Under CT guidance, ^125Ⅰ seeds were implanted pereutaneously into 91 focuses for interstitial radiotherapy according to TPS. Results Of 91 focuses, 23 focuses were CR, 60 were PR, 8 were SD, 0 were PD after 2 month treatment using CT. Total effective rate （ CR ＋ PR） was 91.2%. Effective rate of relieve pain and superior vena cava obstruction was 100.0%. The main complications included pneumothorax in 11 eases, slight hemoptysis of 15 eases and radiation pneumonia of 2 cases. Conclusion CT guided ^125Ⅰ seeds implantation is a safe, reliable and effective method for lung cancer with few complications.
出处
《临床肺科杂志》
2007年第12期1310-1311,共2页
Journal of Clinical Pulmonary Medicine
